Arcturus Therapeutics Holdings Inc. Common Stock (ARCT)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I ask whether a business can produce predictable owner earnings and whether the price offers protection on the downside. Arcturus is an mRNA medicine developer with two Phase 2 candidates, but the financial record is not that of a durable franchise. Revenue has collapsed: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $3.0 million and net income was -$23.8 million, or -$0.84 per diluted share. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $2.1 million and net loss was $27.0 million, or -$0.95 per diluted share. For FY2025, period ended 2025-12-31, revenue was $82.0 million and net loss was $65.8 million, or -$2.40 per diluted share, down from FY2024 revenue of $152.3 million and FY2023 revenue of $166.8 million. The data provided show revenue growth of -96.41%. FairStock's figures show trailing free cash flow of -$72.8 million and a -21.3% FCF yield. The balance sheet has low debt with a D/E of 0.13, but an Altman Z-score of 0.88 and Piotroski F-score of 4/9 suggest fragility. At the 2026-10-13 close of $12.03 and a $341.9 million market cap, P/B is 1.99, while P/E is negative because there are no profits. The Lynch category is TURNAROUND, based on a loss in the latest year after earlier profits. No clear moat is visible in the numbers; the science may be valuable, but it is not yet commercial proof.

In plain English: Arcturus Therapeutics makes experimental medicines for rare liver and lung diseases. The business looks weak right now: sales have fallen sharply and it is losing money. At $12.03, the price does not look cheap compared with those small sales and losses, so its value depends heavily on future drug tests.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer